Eosinophilic otitis media; state-of-the-art diagnosis and treatment.
Biologics
Bronchial asthma
Chronic eosinophilic rhinosinusitis
Diagnostic criteria
Eosinophilic otitis media
Type 2 inflammation
Journal
Auris, nasus, larynx
ISSN: 1879-1476
Titre abrégé: Auris Nasus Larynx
Pays: Netherlands
ID NLM: 7708170
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
29
10
2022
revised:
11
11
2022
accepted:
21
11
2022
medline:
19
6
2023
pubmed:
18
12
2022
entrez:
17
12
2022
Statut:
ppublish
Résumé
Eosinophilic otitis media (EOM) is an intractable otitis media with highly viscous middle ear effusion and is usually associated with bronchial asthma. Since the diagnostic criteria of EOM were established in 2011, the concept of EOM has been known worldwide. EOM is caused by Type 2 inflammation in the respiratory tract, similar to bronchial asthma and eosinophilic rhinosinusitis. With the appreciation of Type 2 inflammatory diseases, EOM is no longer considered to be a rare disease and should be specifically treated to improve quality of life. The diagnosis of EOM needs to be reconsidered because many reports have described varying pathogenesis and mechanisms of rare middle ear conditions. Systemic and topical administration of corticosteroids is presently the most effective treatment to control EOM. However, EOM treatments are developing because various biologics have been used to treat patients with bronchial asthma with and without eosinophilic rhinosinusitis and EOM. Surgical intervention is also no longer contraindicated with the use of biologics. These advances represent the beginning of a new stage of basic and clinical research for EOM. This review focuses on the diagnosis and treatment of EOM based on the most recent advances regarding EOM.
Identifiants
pubmed: 36528403
pii: S0385-8146(22)00225-5
doi: 10.1016/j.anl.2022.11.004
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
479-489Informations de copyright
Copyright © 2022. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Disclosure Statement We have no conflicts of interest to disclose in connection with this review.